# Ursula A. Matulonis

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ursula-a-matulonis/

## Facts

| Field | Value |
| --- | --- |
| Citations | 44,460 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 104 |
| i10-index | 348 |
| OpenAlex ID | https://openalex.org/A5058249824 |
| ORCID iD | https://orcid.org/0000-0002-3103-6992 |
| Works | 1,099 |

## Researcher papers

Showing 12 of 18.

- [Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer](https://scholariq.org/papers/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer/)
- [Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial](https://scholariq.org/papers/oral-poly-adp-ribose-polymerase-inhibitor-olaparib-in-patients-with-brca1-or/)
- [Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer](https://scholariq.org/papers/olaparib-maintenance-therapy-in-platinum-sensitive-relapsed-ovarian-cancer/)
- [Ovarian cancer](https://scholariq.org/papers/ovarian-cancer/)
- [A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors](https://scholariq.org/papers/a-single-cell-and-single-nucleus-rna-seq-toolbox-for-fresh-and-frozen-human/)
- [Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health](https://scholariq.org/papers/place-of-death-correlations-with-quality-of-life-of-patients-with-cancer-and/)
- [Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer](https://scholariq.org/papers/phase-ii-study-of-bevacizumab-in-patients-with-platinum-resistant-ovarian-cancer/)
- [Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1](https://scholariq.org/papers/association-of-polymerase-e-mutated-and-microsatellite-instable-endometrial/)
- [Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial](https://scholariq.org/papers/niraparib-monotherapy-for-late-line-treatment-of-ovarian-cancer-quadra-a/)
- [Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer](https://scholariq.org/papers/adjuvant-chemotherapy-plus-radiation-for-locally-advanced-endometrial-cancer/)
- [Institutional implementation of clinical tumor profiling on an unselected cancer population](https://scholariq.org/papers/institutional-implementation-of-clinical-tumor-profiling-on-an-unselected-cancer/)
- [Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study](https://scholariq.org/papers/efficacy-and-safety-of-mirvetuximab-soravtansine-in-patients-with-platinum/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [vaccines and immunoinformatics approaches](https://scholariq.org/topics/vaccines-and-immunoinformatics-approaches-2/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.